FDA Actions

September 2008
Travel Medicine Advisor;Sep2008 Supplement, Vol. 18, p2
This section provides updates on actions made by the U.S. Food and Drug Administration (FDA) as of September 2, 2008. The FDA has ordered safety-related changes to the labeling of erythropoietin products. The agency has approved the first generic divalproex for the treatment of seizures and bipolar disorder. The FDA has also added a Boxed Warning to fluoroquinolone antibiotics regarding the risk of tendinitis and tendon rupture.


Related Articles

  • Look for a boxed warning against intrathecal use on contrast agents. Rodman, Morton J.; Hurley, Mary Lou // RN;Dec93, Vol. 56 Issue 12, p79 

    Reports on the request by the Food and Drug Administration (FDA) for contrast agents to carry a boxed warning on carton, vial and package inserts that reads `Not For Intrathecal Use'. `FDC Reports' as source; Severe reactions of patients.

  • FDA moves to overhaul package inserts, cut ADEs. Conlan, Michael F. // Drug Topics;1/15/2001, Vol. 145 Issue 2, p47 

    Reports that the United States Food and Drug Administration (FDA) is proposing a format for prescription drug package inserts that could save billions in hospital costs by reducing adverse drug events. Other benefits of the regulation; Remarks from FDA Commissioner Jane E. Henney; Changes in...

  • FDA extends deadline for MedGuide views.  // Drug Topics;11/20/95, Vol. 139 Issue 22, p7 

    Reports on the extension of deadline for comments on the Food and Drug Administration's `Prescription Drug Product Labeling: Medication Guide' proposed rule.

  • FDA issues guidance on safety labelling.  // Reactions Weekly;8/10/2013, Issue 1465, p3 

    The article reports on the "Safety Labelling Changes-Implementation of Section 505(o)(4) of the FD&C Act" guidance released by the U.S. Food and Drug Administration (FDA) to clarify the safety labelling changes that may be required under Section 505(o)(4) of the act.

  • Worth writing for....  // Arthritis Today;Jul/Aug93, Vol. 7 Issue 4, p12 

    Presents contact information on how to secure data about labeling requirements and warnings for over-the-counter medicines. Free publication `Safe and Sure Self-Care with Over-the-Counter Medicines' by the Food and Drug Administration.

  • Drop radiopharmaceuticals from pediatric rule? Dickinson, James G. // Medical Marketing & Media;Jun98, Vol. 33 Issue 6, p34 

    Reports that University of California, Los Angeles (UCLA) professor of radiological sciences, Carol S. Marcus, is requesting that the United States Food and Drug Administration, remove all radiopharmaceuticals from its draft list of approved drugs, needing pediatric labelling. Reasons cited for...

  • GnRH agonists warning.  // MPR - Urologists' Edition;Fall2010/Winter2011, Vol. 7 Issue 1, pA6 

    The article reports on the notification issued by the Food and Drug Administration (FDA) to the manufacturers of Gonadotropin-Releasing Hormone (GnRH) agonists regarding the additional safety information that should be placed on drug labels to warn perople on the increased risk of diabetes and...

  • FDA loking for a few, good words to clarify drug usage. Conlan, Michael F. // Drug Topics;10/24/94, Vol. 138 Issue 20, p73 

    Reports on the Food and Drug Administration's (FDA) search for words to clarify drug usage for a possible change in labeling rules for over-the-counter (OTC) drugs. Loss of impact of repetitive terms; Use of negative terms for the most important warnings; Approval of word pairs that can be used...

  • FDA lays down new rules on pediatric dosing. Conlan, Michael F. // Drug Topics;1/9/95, Vol. 139 Issue 1, p68 

    Reports on the changes in the US Food & Drug Administration's (FDA) regulation of pediatric drugs. Terms in the labeling of pediatric drugs; Clarification of pediatric use statements.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics